InvestorsHub Logo
Followers 0
Posts 69
Boards Moderated 0
Alias Born 01/26/2006

Re: Do DD post# 3329

Saturday, 11/11/2006 6:58:35 AM

Saturday, November 11, 2006 6:58:35 AM

Post# of 6489
During CC Young says:

We continued our label expansion studies for IPLEX and now we have ongoing clinical studies where we are evaluating the
value of IPLEX in several disease areas, such as severe insulin resistance, myotonic muscular dystrophy, AIDS [unintelligible]
dystrophy and we're about to initiate a new clinical study in children with Newman's Syndrome.
Positive data from our severe insular resistance study and our pivotal IGFD studies were presented at several [unintelligible] of the Congress this last quarter and we hope to present top-line data from these new studies in the first half of 2007.
(page 2)

In Q&A part:

The timing for the next data either from severe resistant myotonic muscular dystrophy, AIDS [like] dystrophy, when can we expect to see the next data?
Phil Young - Insmed Incorporated - Chief Business Officer
We expect to see it in early '07 for everything you just mentioned.
http://preview.tinyurl.com/y2hm6x

There's NO mention of PhII results. PY is expecting DATA on all studies somewhere during H1-2007.

CF
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INSM News